Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERANTI: Corabotase in the Prevention of Episodic or Chronic Migraine
NCT06625060Phase 2Active, not recruiting
- Sponsor
- Ipsen
- Start
- Oct 2024
- Primary completion
- Oct 2027
- Modality
- Therapeutic Enzymes
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of corabotase in episodic migraine and chronic migraine (10 arms), sponsored by Ipsen. Primary endpoints: Adverse Events at Week 36, Laboratory Parameters at Week 36 and 7 more. Started Oct 2024; status: active, not recruiting.
02
Drugs
corabotase
03
Conditions
episodic migrainechronic migraine
Beyond the preview
Go deeper on NCT06625060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06625060.